Announcement on Subsidiary MWN110 Injection Obtaining Drug Clinical Trial Approval Notice

Lepu Medical Technology (Beijing) Co., Ltd.·July 15, 2026·2 pages

✨ AI Summary

Lepu (Beijing) Medical Device Co., Ltd. announces that its subsidiary Shanghai Minwei Biotechnology Co., Ltd. has received approval for the clinical trial of MWN110 Injection for adult weight management. Pre-clinical studies show significant efficacy and safety. This marks a crucial step in the drug's development, with potential to offer differentiated outcomes compared to traditional GLP-1 drugs.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300003

Securities Abbreviation: Lepu Medical

Announcement No.: 2026-050

Lepu (Beijing) Medical Device Co., Ltd.

Announcement on Subsidiary MWN110 Injection Obtaining Drug Clinical Trial Approval Notice

The Company and all members of the Board of Directors guarantee the content of the information disclosed is true, accurate, and complete, and that there are no false representations, misleading statements, or material omissions.

Lepu (Beijing) Medical Device Co., Ltd. (hereinafter referred to as the "Company") learned today that its控股 subsidiary Shanghai Minwei Biotechnology Co., Ltd. (hereinafter referred to as "Shanghai Minwei Biotechnology") received the "Drug Clinical Trial Approval Notice" (Notice No.: 2026LP02143) issued by the National Medical Products Administration. The clinical trial application for MWN110 Injection, filed by Shanghai Minwei Biotechnology, has been approved. The relevant situation is hereby announced as follows:

I. Information on the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.